Review Article

The Pathological Roles of Ganglioside Metabolism in Alzheimer’s Disease: Effects of Gangliosides on Neurogenesis

Toshio Ariga, Chandramohan Wakade, and Robert K. Yu

Institute of Molecular Medicine and Genetics and Institute of Neuroscience, Medical College of Georgia, 15th street, Augusta, GA 30912, USA

Correspondence should be addressed to Robert K. Yu, ryu@mcg.edu

Received 20 October 2010; Accepted 8 December 2010

Academic Editor: Katsuhiko Yanagisawa

Copyright © 2011 Toshio Ariga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conversion of the soluble, nontoxic amyloid β-protein (Aβ) into an aggregated, toxic form rich in β-sheets is a key step in the onset of Alzheimer’s disease (AD). It has been suggested that Aβ induces changes in neuronal membrane fluidity as a result of its interactions with membrane components such as cholesterol, phospholipids, and gangliosides. Gangliosides are known to bind Aβ. A complex of GM1 and Aβ, termed “GAβ,” has been identified in AD brains. Abnormal ganglioside metabolism also may occur in AD brains. We have reported an increase of Chol-1α antigens, GQ1bα and GT1aα, in the brain of transgenic mouse AD model. GQ1bα and GT1aα exhibit high affinities to Aβs. The presence of Chol-1α gangliosides represents evidence for genesis of cholinergic neurons in AD brains. We evaluated the effects of GM1 and Aβ1–40 on mouse neuroepithelial cells. Treatment of these cells simultaneously with GM1 and Aβ1–40 caused a significant reduction of cell number, suggesting that Aβ1–40 and GM1 cooperatively exert a cytotoxic effect on neuroepithelial cells. An understanding of the mechanism on the interaction of GM1 and Aβs in AD may contribute to the development of new neuroregenerative therapies for this disorder.

1. Introduction

Alzheimer’s disease (AD) is an irreversible, slowly progressive neurodegenerative disease that is the most common form of dementia among people age 65 and older and is characterized by cognitive and behavioral problems. The symptoms are initiated by memory loss and gradually lead to behavior and personality changes with impaired cognitive abilities such as decline of decision making and language disability, and eventually disturbances in recognizing family and friends. These losses are related to the worsening lesion of the connections between certain neurons in the brain. Patients often become anxious or aggressive, or wander away from home. Eventually, patients need total care, and the final outcome is always death. Although there is no cure at present, some therapeutic drugs inhibiting acetylcholinesterase have been used to alleviate the disease symptoms and improve the quality of life for patients with AD [1, 2].

Gangliosides are important constituents of cells; they are especially abundant in neuronal membranes and play a variety of biological functions, including cellular recognition and adhesion as well as signaling [3]. The expression of gangliosides is not only cell type specific and developmentally regulated but also closely related to the differentiation state of the cell [3–6]. Numerous studies have indicated that changes of ganglioside expression patterns and levels during cellular differentiation are closely related to their metabolism, particularly their biosynthesis [3, 4, 6]. Notably, gangliosides may have neuroprotective effects to the cell [7]. Gangliosides do not function as a neurotrophic factor themselves, but they potentiate neurotrophic influences present in the nervous system. In this regard, many scientists have reported the beneficial effects of GM1 treatment in animal models of neurodegeneration and diseases. For example, administration of GM1 protects hippocampal progenitor cells from neuronal injury and reduces hippocampal neurogenesis induced by D-galactose treatment [8]. Saito et al. reported that GM1 and LIGA20 can protect mouse brains from apoptotic neurodegeneration induced by ethanol [9]. In clinical applications or animal studies, many studies have
The pathological hallmarks in the AD brain include senile plaques (SPs) and neurofibrillary tangles. Many scientists believe that the accumulation and aggregation of amyloid β-proteins (Aβs) in SPs in the brain are a central part of the pathogenesis of AD. The conversion of soluble, nontoxic Aβ into aggregated, toxic Aβ rich in β-sheet structures is considered to be the key step in the development of AD. Aβs are able to bind to a variety of biomolecules, including lipids, proteoglycans, and certain proteins [1, 16]. Immunochemical studies revealed that Aβ deposits in AD brain are due to the presence of certain amyloid-associated proteins such as amyloid P component, proteoglycans, and apolipoproteins [17]. The potential significance of the interaction with proteoglycans and Aβs for the pathogenic mechanisms has been reviewed [2].

During aging and neurodegeneration in AD, the physicochemical properties of membranes and lipid metabolism undergo significant alterations [18, 19]. These include multiple changes such as glycosphingolipid (GSL) abnormalities involving membranes and lipid metabolism [20]. These changes can result in imbalances in the proportion of lipids in membranes and/or changed ratios of membrane lipids, which may contribute to the pathogenesis of AD [21–23]. Earlier immunohistochemical studies on the involvement of GSLs using specific monoclonal antibodies revealed that SPs contained GM1 [24], c-series gangliosides [25], and GD1α [26], and these studies implicated that Aβs might be interacting with the above gangliosides. In this paper, we will focus on the role of ganglioside metabolism in the pathogenesis and/or development of AD.

2. Interaction of Amyloid β-Proteins with Gangliosides

A critical question concerning the development of AD is how the soluble, nontoxic Aβ form high in an α-helix-rich structure is converted into an aggregated, toxic form rich in β-sheets in the brain. Terzi et al. first reported that Aβ1–40 undergoes a conformational transition from random coil to aggregated structure rich in β-sheet after addition of lipid vesicles containing negatively charged lipids [27], suggesting that Aβ neurotoxicity may be the result of membrane protein-lipid interactions. Several studies have demonstrated that Aβs bind to gangliosides, especially GM1, resulting in an altered secondary structure of Aβs [28–31]. Aβ binds to membranes containing ganglioside GM1, and upon binding it undergoes a conformational transition from random coil to an ordered structure rich in β-sheet. This interaction appears to be ganglioside-specific because no changes in Aβ1–40 conformation were found in the presence of various phospholipids or sphingomyelin. Aβ binds selectively to gangliosides with a binding affinity ranging from 10^{-6} to 10^{-7} M, depending on the type of the sugar moiety present in the ganglioside molecule. On the other hand, the isolated oligosaccharide moieties of gangliosides are ineffective in inducing alterations in the secondary structure of Aβ1–40 [28, 32], suggesting the involvement of the lipid component in their interaction. The sialic acid (NeuAc) moiety of gangliosides interacts with Aβ to induce conformational changes in Aβ [31]. In this regard, we have reported that Aβ1–40 binds to a number of gangliosides with the following order of binding strength: GQ1bα > GT1aα > GQ1bβ > GT1bβ > GD3 > GD1α = GD1bβ > LM1 > GM1 > GM2 = GM3 > GM4 based on surface plasmon resonance studies [33]. Neutral GSLs, including asialo-GM1, generally have a much lower affinity for Aβ1–40 than do gangliosides. The results suggest that the α2,3NeuAc residue on the oligosaccharide core of gangliosides is required for binding. In addition, the α2,6NeuAc residue linked to GalNAc in the α-series of gangliosides contributes significantly to the binding affinity for Aβ. Although several reports documented the GM1-induced alterations in the β-sheet structure of Aβ, Mandel and Pettegrew, on the other hand, reported that GM1 inhibited Aβ from undergoing α-helix to β-sheet conformational changes [34]. This discrepancy clearly needs further clarification. In addition, asialo-GM1 binds specifically with Aβ in a manner that could prevent β-sheet formation. Nakazawa et al. reported that Aβ1–40 strongly perturbed the lipid bilayer structure of liposomes of dimyristoylphosphatidylcholine and GM1 to form a nonlamellar phase (most likely in the micellar phase) [35]. The α-helical peptide conformation is significantly flexible and is approximately equally partitioned between components penetrated into the bilayer and in liquid phase whereas the β-sheet peptide conformation is rigid and is presumably deposited and stacked at the bilayer surface.

The interaction between gangliosides and Aβ appears to be affected by experimental conditions such as pH, ionic strength [30, 31], and metal ions [36, 37]. For example, McLaurin and Chakrabartty have reported that Aβ1–40/Aβ1–42 disrupts acidic lipid membranes, and this disruption is greater at pH 6.0 than at pH 7.0, at which point gangliosides induce Aβ1–40/Aβ1–42 to adopt a novel α/β conformation [30]. A further study indicated that binding of Aβ1–40 to mixed gangliosides or GM1-containing vesicles induced an α-helical structure at pH 7.0 and β-sheet structure at pH 6.0 [31]. Several lines of evidence have indicated that disruption of the homeostatic balance of redox-active biometals such as Cu and Fe can lead to oxidative stress, which plays a key role in the development of AD. Atwood et al. reported that unlike other biometals tested at maximal biological concentrations, Cu^{2+}-induced aggregation of Aβ1–40 occurred as the solution pH was lowered from 7.4 to 6.8 and that the reaction was completely reversible with either chelation or alkalinization [36]. The aggregation-inducing activity of metals is in the following order, Cu^{2+} > Fe^{3+} or = Al^{3+} > Zn^{2+} [37].

3. Binding Sites of Amyloid β-Proteins with Gangliosides

The NeuAc residue of the ganglioside head group is important for determining the nature of the conformational change
of Aβ [31, 38] or interaction with Aβ [33]. The isolated pentasaccharide head group of GM1 alone, however, does not bind with Aβ, suggesting the need for a polyanionic membrane-like structure [38]. To provide a structural basis for this pathogenic interaction associated with AD, Williamson et al. have demonstrated using NMR on 13N-labelled Aβ1–40 and Aβ1–42 that the interaction with GM1 micelles is localized to the N-terminal region of the peptide, particularly residues His13 to Leu17, which become more helical when GM1 is bound [38]. The key interaction is with His13, which undergoes a GM1-specific conformational change. Zhang et al. reported that the binding site for GM1 was located within residues 52–81 (N terminus) of amyloid precursor protein (APP), resulting in a conformational change of APP [39]. This phenomenon is specific for GM1, but not for GD1α, GT1b, and ceramide, indicating that specific binding depends on the sugar moiety of GM1.

Utsumi et al. reported the association of Aβ1–40 isoelectrically labeled with GM1 and lyso-GM1 micelles using 920 MHz ultra-high field NMR analyses [40]. The data revealed that: (a) Aβ1–40, upon binding to the gangliosidic micelles, forms discontinuous α-helices at the segments His(14)-Val(24) and Ile(31)-Val(36), and (b) Aβ1–40 lies on hydrophobic/hydrophilic interface of the ganglioside cluster, exhibiting an up-and-down topological mode in which the two α-helices and the C-terminal dipeptide segment are in contact with the hydrophobic interior whereas the remaining regions are exposed to the aqueous environment. These results suggest that the ganglioside clusters serve as a unique platform for binding coupled with conformational transition of Aβ molecules, rendering their spatial rearrangements restricted to promote specific intermolecular interactions [40]. Further study of NMR analyses of the Aβ interactions with gangliosides using lyso-GM1 micelles as a model system have revealed that the sugar-lipid interface is primarily perturbed upon binding of Aβ to the micelles, underscoring the importance of the inner part of the ganglioside cluster for accommodating Aβ in comparison with the outer carbohydrate branches that provide microbial toxin- and virus-binding sites [41].

4. Accumulation of Specific Ganglioside-Bound Amyloid β-Protein Complex (GAβ) in AD Brain

Choo-Smith et al. have reported that addition of ganglioside-containing vesicles to the Aβ solution dramatically accelerates the rate of fibril formation compared to vesicles without gangliosides [28]. The mechanism of ganglioside-mediated Aβ-fibrillation likely involves an initial step in which the GSL-bound peptide self-associates on the membrane surface, undergoing a conformational transition to a β-sheet structure. This suggests that gangliosides can mediate Aβ assembly to lead to accumulation in the brain, which may be involved in the development of AD. Yanagisawa et al. first reported the presence of membrane-bound Aβ1–42, but not Aβ1–40, which tightly binds to GM1 in the AD brain [42]. This novel Aβ species, named as ganglioside-bound Aβ (GAβ), may act as an endogenous seed for amyloid [42], and exhibited early pathological changes of amyloid [42], and exhibited early pathological changes of amyloid. It was hypothesized that Aβ adopts an altered conformation following interaction with GM1, leading to the generation of GAβ, and then GAβ acts as an endogenous seed for amyloid in AD brain. GAβ has unique characteristics, including an extremely high aggregation potential and an altered pattern of immunoreactivity, which results in seeding for amyloid fibril formation in brain. Thus, GAβ may serve as a seed for toxic amyloid fibril formation. The formation of GAβ serves as one of the critical factors in the development of AD and may provide new insights into the pathophysiology in AD [43]. The occurrence of GAβ in AD brain was further confirmed biochemically by staining with cholera toxin B subunit (CTXB) that preferentially binds to GM1, and by immunoprecipitation experiments using several anti-Aβ monoclonal antibodies [44]. Recently, the presence of GAβ was confirmed in sections of cerebral cortices of cynomolgus monkeys of different ages, from 4 to 36 years old; especially, GAβ is significantly increased in the brains at ages below 19 years [45]. In this study, the accumulation of GAβ occurred exclusively in the subcellular organelles that are involved in the endocytic pathway. Since Aβ generation and GM1 accumulation likely occur in early endosomes, it suggests that endosomes are intimately involved in the Aβ-associated pathology of AD [45]. In addition, Aβ aggregation in brain is accelerated through an increase in the level of GM1 in neuronal membranes [46, 47]. The effect occurs in a dose-dependent manner; in the presence of lower concentrations of GM1 (approximately 25 μM), Aβ1–40 forms aggregates much more slowly, indicating that an increase in the concentration of GM1 significantly facilitates the aggregation of Aβ. Further studies have indicated that both GM1 and GT1b promote the aggregation and cytotoxicity of Aβ1–40, and these gangliosides, especially GM1, catalyze the formation of neurotoxic fibrils [48]. Moreover, binding of Aβ to GM1 was dependent on cholesterol-induced clustering of GM1 in the host membranes. An increase in the cholesterol concentration in the neuronal membranes accelerates Aβ aggregation through the formation of an endogenous seed [49, 50], consistent with the notion that cholesterol is also a risk factor for AD development. These results further underscore the importance of control of cellular cholesterol and/or ganglioside contents in the pathogenesis of AD [50–52]. Lin et al. reported the role of GM1 and cholesterol on the Aβ-induced cytotoxicity in the plasma membrane [33]. Depletion of GM1 from the plasma membrane would be expected to block the Aβ-induced cytotoxicity. Decreasing the cholesterol level by around 30% could also attenuate the cytotoxicity of Aβ. These findings validate that cholesterol can stabilize the lateral pressure derived from formation of the GM1-Aβ complex on the membrane surface and that both GM1 and cholesterol are essential for Aβ accumulation. Zha et al. reported that GM1 regulated the expression of Aβ in a dose-dependent manner [54]. Exogenously added GM1 increased Aβ levels in mixed rat cortical neurons containing African green monkey epithelial kidney cells (COS7) and human neuroblastoma cells (SH-SY5Y) that were transfected with APP695 cDNA.
Yanagisawa and co-investigators developed a novel monoclonal antibody, 4396C, raised against GAβ purified from an AD brain [55]. Using this antibody, the presence of GAβ was confirmed in the AD brain, in which GAβ is endogenously generated. The antibody reacted with GM1-bound forms of two Aβ isoforms, Aβ1–40 and Aβ1–42, but not the unbound forms of Aβ1–40 and GM1. Remarkably, using liposomes containing Aβ1–40 and GM1, this antibody completely blocks amyloid fibril formation in a dose-dependent manner, suggesting that it may act to inhibit the initiation of oligomerization-polymerization of Aβ in the brain and serve in the possible development of a novel therapeutic strategy to the GAβ-dependent amyloidogenesis [55, 56]. The age-dependent high-density GM1 clustering at the presynaptic neuritic terminals is a critical step for Aβ deposition in AD. In amyloid-positive synaptosomes prepared from AD brain, GM1 levels are significantly increased when Aβ deposition begins at presynaptic terminals. The antibody against GAβ, 4396C, suppressed Aβ assembly in the synaptosomes [57]. Moreover, peripheral administration of the Fab fragments of 4396C into transgenic mice expressing a mutant amyloid precursor protein gene, following the conjugation of the protein transduction domain of the Tat protein, markedly suppressed Aβ deposition in the brain [58].

Interestingly, the enhanced GAβ-dependent amyloidogenesis under the endocytic dysfunction was suppressed by pretreatment with a sphingomyelinase synthase inhibitor, suggesting that sphingomyelin is also one of the key molecules for GAβ generation, further implying that the interaction of Aβ with membrane lipids is critical in amyloid fibrillization in the brain [59]. In addition, the expression of apolipoprotein E4 may facilitate Aβ assembly in the brain through an increase in the GM1 content in neuronal membranes, which likely induces GAβ generation [43, 47, 60].

In recent years, evidence has been presented that “lipid rafts” are the preferential sites for the formation of the pathological forms of Aβ [61]. GAβ is generated in the membrane raft-like microdomains, comprised of cholesterol, sphingomyelin, and GM1 [62, 63], in which Aβ undergoes a conformational transition from an α-helix-rich structure to a β-sheet-rich structure or oligomerization with the increase in protein density on the membrane. GM1 induced amyloid fibrillization, especially under β-sheet-forming conditions, leading to the generation and seeding of GAβ. Thus, ganglioside binding with Aβ is the initial and common step in the development of a part of human misfolding-type amyloidoses, including AD [64]. The level of GAβ is increased, and its α-helix structure is converted into a β-sheet structure [65]. Thus, the formation of amyloid fibrils or oligomers is likely mediated by gangliosides in lipid rafts [66], and depletion of gangliosides or cholesterol significantly reduces the amount of amyloid deposits [48, 67].

5. Other Gangliosides May Be Involved In the Generation of GAβ

Other gangliosides have been shown to interact with Aβ, which may lead to Aβ accumulation in the brain. The assembly of wild-type and mutant forms of Arctic-, Dutch-, and Flemish-type of Aβs is accelerated in the presence of not only GM1, but also GM3 and GD3 gangliosides. Dutch and Italian-type Aβs require GM3 ganglioside for their assembly [47]. Arctic-type Aβ, in contrast to the wild-type and other variant forms, shows a markedly rapid and higher level of amyloid fibril formation in the presence of sodium dodecyl sulfate or GM1 ganglioside [68]. These results provide evidence that local gangliosides play a crucial role in the region-specific Aβ deposition in the brain [69, 70]. Gangliosides are located mostly on the cell surface and have been demonstrated to modulate neurotrophic activities. The localization of GD1a in dystrophic neurites suggests that such neurites accumulate GD1a as a membranous component. In addition, the accumulation of GD1a in SPS suggests that it may contribute to SP formation [26]. In a study for the interaction of Aβs with GM1 using rat adrenal medulla pheochromocytoma cells (PC12 cells), Wakabayashi et al. used CTXB for detection of GM1 [71]. However, the ganglioside that interacted with Aβs in PC12 cells may not be definitively GM1 because CTXB also strongly reacted also with fucosyl-GM1 and fucosyl-GD1b [72] and PC12 cells express fucosyl gangliosides including fucosyl-GM1 [73, 74] with little or no GM1 [75]. When PC12 cells were cultured in the presence of Aβ1–40 or Aβ1–42, Aβs accumulated in cells expressing fucosyl gangliosides [72]. Thus, the interaction of Aβ with gangliosides to effect amyloid assembly may not be limited to GM1; indeed, other gangliosides should also be involved in “seeding” [1, 72]. Molander-Melin et al. reported that the detergent-resistant membrane fractions from the frontal cortex of AD brains contained a significantly higher concentration of ganglioside GM1 and GM2 [76]. The increased proportions of GM1 and GM2 in lipid rafts at an early AD stage could accelerate the formation of Aβ plaques, which gradually causes membrane raft disruptions and thereby affects cellular functions that are dependent on the presence of such membrane domains.

6. Ganglioside Metabolism in AD Brains and AD Model Mouse Brains

Aβ changes in membrane fluidity could be induced by chemical interactions of the peptide with membrane components such as cholesterol, phospholipids, and gangliosides [77]. Since gangliosides have a strong affinity to Aβs [33], they could participate in conformational changes of Aβs in membrane fluidity. For this reason, ganglioside metabolism has been considered to be closely associated with the pathogenesis of AD [1, 20]. Several earlier studies showed significant changes of ganglioside patterns in AD brain. The concentration of gangliosides decreased in the majority of brain regions, such as the cerebral cortex, hippocampus, and basal telencephalon, especially in the frontal cortex and white matter [78–80]. Kracun et al. reported that the major brain ganglio-N-tetraosyl-series ganglioside species (GT1b, GD1b, GD1a, and GM1) significantly decreased in the frontal and temporal cortices and basal telencephalon of the brains of patients with AD compared with the respective areas in control brain [81, 82]. Brooksbank and
McGovern [83] and Crino et al. [84] also reported changes of ganglioside composition in AD brains in which b-series gangliosides, such as GD3, were completely absent, but GM1 and GD1a were significantly increased. Interestingly, Aβ accumulation and AD. Thus, inhibition of GD3-synthase can be a novel therapeutic target to combat the cognitive deficits, amyloid plaque formation, and neurodegeneration seen in AD.

In this regard, Okada et al. reported that endogenously generated b-series gangliosides may be critical for...
the repair of damaged neural tissues in vivo [101]. They established a GD3-synthase gene knockout mouse model in which all b-series gangliosides were deleted. However, animals showed no morphological changes in the brains and apparent abnormal behavior. Moreover, no differences in Fas-mediated apoptotic reaction in lymphocytes compared with the wild type were found. The mutant mice, however, exhibited reduced regeneration of axotomized hypoglossal nerves compared with the wild type, suggesting that b-series gangliosides are more important in the repair of damaged nerves rather than in the differentiation of the nervous system.

7. Neurogenesis and Neural Stem Cells in AD Brain

The neurodegenerative process in AD is initially characterized by synaptic damage accompanied by neuronal loss. Neuronal loss leads to cerebral atrophy, which appears to be hallmarks of cognitive impairment in AD [102]. In addition to the alterations in synaptic plasticity and neuronal integrity in mature neuronal circuitries, the neurodegenerative process in AD has recently been shown to be accompanied by alterations in neurogenesis [103, 104]. The hippocampus is one of the regions in the adult brain where neurogenesis occurs throughout life [5]. Many studies have shown that adult neurogenesis is involved in learning and memory. This has led to the hypothesis that impairment in memory during aging and neurodegenerative diseases such as AD involves abnormal neurogenesis [105]. However, neurogenesis in AD and in animal models is not fully studied yet [106]. In AD brains, there is some controversy whether neurogenesis is increased [107] or decreased [107]. Boekhoom et al. reported an apparent increase of neurogenesis markers in AD brains, which may be related to glial and vasculature-associated changes [107]. A number of mouse models of AD displayed reduced neurogenesis [108–110] or enhanced neurogenesis [97]. Several attributes of adult hippocampal neurogenesis suggest that amyloid deposition may influence neurogenesis [111]. Zhang et al. reported that reductions in dentate gyrus neurogenesis in a murine model of amyloid deposition are linked to the deposition of amyloid [112].

The adult mammalian brain contains neural stem cells (NSCs), undifferentiated neural cells characterized by their high proliferative potential and the capacity for self-renewal with retention of multipotency to differentiate into neurons and glial cells, in the subgranular zones of dentate gyrus
and the subventricular zone (SVZ) of the lateral ventricles [5]. The possibility that abnormalities in NSCs contribute to the pathogenesis of AD and the cognitive impairments in humans has been suggested [109, 110]. Several papers have described the phenomenon of neurogenesis in hippocampus, and it seems to be enhanced in AD brains. This phenomenon could potentially occur also in the brain of animal models of AD, which points to the possibility of developing strategies for promoting neurogenesis for AD therapy by using NSCs. A number of studies have indicated that Aβs can regulate the proliferation of NSCs and documented the bifunctional roles of Aβs on the cells in a dose-dependent manner. The low concentrations of Aβs have neurogenic effects in some studies [115–117] but cytotoxic effects in other studies [109, 118, 119]. Soluble oligomers of Aβ1–40 and Aβ1–42, but not Aβ40–1, a reversed amino acid sequence, induced neuronal apoptosis [120]. The aggregated form of Aβ1–42 stimulated neurogenesis [117, 121]. In this regard, Aβ1–40 (0.5 μmol/L), did not affect their proliferation [122]. Gong et al. reported that small, soluble oligomers of Aβ block the reversal long-term potentiation [123]. Controversially, a low micromolar concentration (1 μM) of oligomeric Aβ1–42 increased the proliferation [124] and neurogenesis of adult NSCs [117]. Small peptide, Aβ1–16, had no effect on neuronal proliferation of adult SVZ progenitors [119, 121]. Several studies indicated that Aβ25–35 has toxic effects and may induce cell death or apoptosis [109, 110, 118, 125, 126]. In contrast, Li and Zuo reported inhibitory effects of aggregated form of Aβ25–35 (1 mg/mL, 3 μL) on neurogenesis in the SVZ and dentate gyrus after injection into the lateral ventricle of adult mouse [127]. This result indicates that Aβ25–35 could impair neurogenesis in the hippocampus of adult mouse brain.

In neuronal cultures prepared from rat hippocampi (embryonic day 18 to 19), it was reported that 25 μM of Aβ25–35 enhanced the metabolism of lipids such as phospholipids (+52%) and gangliosides (+193%), but not cholesterol [128]. In addition, exposure of rat cultured cortical
neurons to Aβ25–35 induced a substantial increase of the intracellular GD3 levels [129]. These reports suggest that Aβ can modulate ganglioside metabolism in NSCs. It has been reported that in NSCs, GSLs, including gangliosides, are involved in cellular proliferation via modulation of the Ras-mitogen-activated protein kinase pathway [114]. These findings prompt us to propose that a combination of Aβ and GM1 induces NSC proliferation. Recently, we evaluated the effects of GM1 and Aβ1–40 on mouse neuroepithelial cells (NECs) that are known to be abundant in NSCs [130]. In NECs cultured in the presence of lower concentrations of GM1 (1, 5 or 10 μM) and/or Aβ1–40 (1 or 5 μM), there was no drastic change of the cell number (Figure 3(a)). However, in NECs cultured in the presence of both 40 μM of GM1 and 10 μM of Aβ1–40, a significant reduction of the cell number was detected (Figure 3(b)). These exogenously added GM1 and Aβ1–40 were efficiently incorporated into NECs (Figure 4). In NECs simultaneously treated with GM1 and Aβ1–40, the Ras-mitogen-activated protein kinase pathway important for proliferation was intact, but caspase-3, an executioner for cell death, was activated. Most NECs treated with GM1 and Aβ1–40 were positive for terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, an indicator of cell death accompanied with DNA fragmentation. These results indicate that Aβ1–40 and GM1 cooperatively exert a cytotoxic effect on NECs, likely via incorporation into NEC membranes where the formation of a complex results in activation of cell death signaling.

Several reports have indicated that gangliosides added exogenously in the culture medium have bifunctional effects on neural cell proliferation. Gangliosides added exogenously at the concentration of micromolar levels were found to inhibit neuritogenesis in human neuroblastoma cells, SH-SY5Y [131]. However, under physiological conditions, GM1 enhanced nerve growth factor-induced neurite outgrowth, neurite complexity, and neuronal cell survival following nerve growth factor withdrawal using fetal-chick dorsal root ganglia [132] and induced neurite sprouting in culture neurons [133]. GQ1b induced phosphorylation of cell surface proteins in a human neuroblastoma cell line, GOTO [134]. The effects of gangliosides exogenously added remained obscure and seem to vary from one cell line to another and the culture conditions [7]. Therefore, further studies are needed to clarify the relationship between GM1 and Aβ in the proliferation of NECs. In addition, evaluation of the effects of exogenous GM1 on neurogenesis and pathogenesis of AD in pathological conditions, for instance, using AD model mice [135] will be an interesting and fruitful subject for future study.
studies. Many studies showed that NSCs improved neuronal survival in cultured postmortem brain tissue from aged and AD patients [136]. Further studies to understand the roles of GM1 and Aβs on NSCs in AD should contribute to the development of new regenerative therapies of this disease.

8. Conclusions

There is increasing consensus that AD is characterized in the brain by aggregated amyloid deposits in SPs. The aggregation of Aβ plays a pivotal role in the pathogenesis of AD that is intimately linked to neuronal toxicity and inhibition of hippocampal long-term potentiation. At present, there is no cure for AD, although some drugs inhibiting acetylcholinesterase have proved to be current treatment to palliate both cognitive and behavioral symptoms within a limited time. Researchers are looking for new treatments to alter the course of the disease and improve the quality of life for patients with AD and related dementia. Aβ is currently clarified to interact with gangliosides with high affinities. In fact, a complex of GM1 (and possibly other gangliosides) with Aβ, termed GAβ, was found to accumulate in the AD brains. An antibody against GAβ was proved to block amyloid fibril formation, suggesting that it can contribute to the development of a novel therapeutic strategy to AD. In this regard, drugs such as nordihydroguaiaretic acid, rifampicin, and tannic acid are found to be potent inhibitors of the binding of GM1 and Aβ, resulting in inhibition of membrane-mediated formation of Aβ fibrils in vitro. These drugs are useful agents for AD therapy [137]. On the other hand, in AD model mice lacking GD3-synthase, Aβ plaques and associated neuropathology are almost completely eliminated, resulting in cognitive improvement. GD3-synthase and its downstream metabolic products, the b-series gangliosides, can be a novel therapeutic target for repressing neurodegeneration and cognitive deficits that afflict AD patients. Another promising therapeutic strategy for AD is cell replacement therapy using NSCs. Although neurogenesis in AD brains is still controversial, transplantation of NSCs into the damaged brain regions may be beneficial for neural regeneration in AD. For therapeutic use of NSCs in AD, however, it should be essential to fully clarify the effects of Aβs and gangliosides on NSC fate regulation. Future therapies for treating AD will include agents that modulate GSL metabolism, either as primary therapeutics or in combination with other drugs.

The nomenclature for gangliosides is based on the system of Svennerholm [138].

Abbreviations

Aβ: Amyloid β-protein
AD: Alzheimer’s disease
APP: Amyloid precursor protein
Chol-1α: Cholinergic-specific antigen-1α
CTXB: Cholera toxin B-subunit
Gaβ: Ganglioside-bound Aβ or a complex of GM1 and Aβ
GSL: Glycosphingolipid
NEC: Neuroepithelial cell
NSC: Neural stem cell
SVZ: Subventricular zone
NeuAc: Sialic acid or N-acetyl neuraminic acid
SP: Senile plaque
Tg: Transgenic
WT: Wild type.

Acknowledgments

This study was supported by USPHS Grants (nos. NS11853, NS26994, and AG027199) to R. K. Yu. The authors are grateful to Dr. Susumu Ando (Tokyo Metropolitan Institute of Gerontology, Japan) for supplying the Chol-1α antigens and the monoclonal antibodies and Dr. Makoto Yanagisawa, Medical College of Georgia, GA for helpful discussions in preparation of this paper.

References

[1] T. Ariga, M. P. McDonald, and R. K. Yu, “Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease—a review,” Journal of Lipid Research, vol. 49, no. 6, pp. 1157–1175, 2008.
[2] T. Ariga, T. Miyatake, and R. K. Yu, “Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer’s disease and related disorders: amyloidogenesis and therapeutic strategies—a review,” Journal of Neuroscience Research, vol. 88, no. 11, pp. 2303–2315, 2010.
[3] R. K. Yu, Y. Nakatani, and M. Yanagisawa, “The role of glycosphingolipid metabolism in the developing brain,” Journal of Lipid Research, vol. 50, pp. S440–S445, 2009.
[4] S. Ngamukote, M. Yanagisawa, T. Ariga, S. Ando, and R. K. Yu, “Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains,” Journal of Neurochemistry, vol. 103, no. 6, pp. 2327–2341, 2007.
[5] M. Yanagisawa and R. K. Yu, “The expression and functions of glycoconjugates in neural stem cells,” Glyobiology, vol. 17, no. 7, pp. 57R–74R, 2007.
[6] R. K. Yu, “Development regulation of ganglioside metabolism,” Progress in Brain Research, vol. 101, pp. 31–44, 1994.
[7] R. W. Ledeen, G. Wu, Z. H. Lu, D. Kozireshkchuback, and Y. Fang, “The role of GM1 and other gangliosides in neuronal differentiation: overview and new findings,” Annals of the New York Academy of Sciences, vol. 845, pp. 161–175, 1998.
[8] Q. Zhang, Y. Huang, X. Li, X. Cui, P. Zuo, and J. Li, “GM1 ganglioside prevented the decline of hippocampal neurogenesis associated with D-galactose,” NeuroReport, vol. 16, no. 12, pp. 1297–1301, 2005.
[9] M. Saito, R. F. Mao, R. Wang, C. Vadasz, and M. Saito, “Effects of gangliosides on ethanol-induced neurodegeneration in the developing mouse brain,” Alcoholism: Clinical and Experimental Research, vol. 31, no. 4, pp. 665–674, 2007.
[10] L. Svennerholm, G. Bråne, I. Karlsson, A. Lekman, I. Ramström, and C. Wikkelso, “Alzheimer disease—effect of continuous intracerebroventricular treatment with GM1
ganglioside and a systematic activation programme,” 
*Dementia and Geriatric Cognitive Disorders*, vol. 14, no. 3, pp. 128–136, 2002.

[11] K. Kawaguchi, N. Kitaguchi, S. Nakai et al., “Novel therapeutic approach for Alzheimer’s disease by removing amyloid β protein from the brain with an extracorporeal removal system,” 
*Journal of Artificial Organs*, vol. 13, no. 1, pp. 31–37, 2010.

[12] Y. Matsuoka, M. Saito, J. LaFrancois et al., “Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid,” 
*Journal of Neuroscience*, vol. 23, no. 1, pp. 29–33, 2003.

[13] J. Schneider, D. Roeltgen, E. L. Mancall, J. Chapas-Crilly, D. S. Rothblat, and G. T. Tatarian, “Parkinson’s disease improved function improved with GM1 ganglioside treatment in a randomized placebo-controlled study,” 
*Neurology*, vol. 50, no. 6, pp. 1630–1636, 1998.

[14] G. L. Lenzi, F. Grigoletto, M. Gent et al., “Early treatment of stroke with monosialoganglioside GM-1: efficacy and safety results of the early stroke trial,” 
*Stroke*, vol. 25, no. 8, pp. 1552–1558, 1994.

[15] R. A. Hughes and D. R. Cornblath, “Guillain-Barré syndrome,” 
*The Lancet*, vol. 366, no. 9497, pp. 1653–1666, 2005.

[16] Y. Verdier and B. Penke, “Binding sites of amyloid β-pleptide in cell plasma membrane and implications for Alzheimer’s disease,” 
*Current Protein and Peptide Science*, vol. 5, no. 1, pp. 19–31, 2004.

[17] T. Wisniewski, J. Ghiso, and B. Frangione, “Biology of Aβ amyloid in Alzheimer’s disease,” 
*Neurobiology of Disease*, vol. 4, no. 5, pp. 313–328, 1997.

[18] N. I. Haughey, “Sphingolipids in neurodegeneration,” 
*Neuro-Molecular Medicine*, vol. 12, no. 4, pp. 301–305, 2010.

[19] N. J. Haughey, V. V. R. Bandaru, M. Bae, and M. P. Mattson, “Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis,” 
*Biochimica et Biophysica Acta*, vol. 1801, no. 8, pp. 878–886, 2010.

[20] T. Mutoh, Y. Hirabayashi, T. Mihara et al., “Role of glycosphingolipids and therapeutic perspectives on Alzheimer’s disease,” 
*CNS and Neurological Disorders-Drug Targets*, vol. 5, no. 4, pp. 375–380, 2006.

[21] G. P. Gorbenko and P. K. J. Kinnunen, “The role of lipid-protein interactions in amyloid-type protein fibril formation,” 
*Chemistry and Physics of Lipids*, vol. 141, no. 1–2, pp. 72–82, 2006.

[22] M. O. W. Grimm, J. A. Tschäpe, H. S. Grimm, E. G. Zinser, and T. Hartmann, “Altered membrane fluidity and lipid raft composition in presenilin-deficient cells,” 
*Acta Neurologica Scandinavica*, vol. 114, no. 185, pp. 27–32, 2006.

[23] P. T. Wong, J. A. Schauer, C. K. Wisser et al., “Amyloid-β membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity,” 
*Journal of Molecular Biology*, vol. 386, no. 1, pp. 81–96, 2009.

[24] N. Iwamoto, Y. Suzuki, Y. Makino, C. Haga, K. Kosaka, and R. Iizuka, “Cell membrane changes in brains manifesting senile plaques: an immunohistochemical study of GM membranous ganglioside,” 
*Brain Research*, vol. 522, no. 1, pp. 152–156, 1990.

[25] H. Takahashi, K. Hirokawa, S. Ando, and K. Ohata, “Immunohistochemical study on brains of Alzheimer’s disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5,” 
*Acta Neuropathologica*, vol. 81, no. 6, pp. 626–631, 1991.

[26] T. Nishinaka, D. Iwata, S. Shimada, K. Kosaka, and Y. Suzuki, “Anti-ganglioside GD1a monoclonal antibody recognizes senile plaques in the brains of patients with Alzheimer-type dementia,” 
*Neuroscience Research*, vol. 17, no. 2, pp. 171–176, 1993.

[27] E. Terzi, G. Holzemmann, and J. Seelig, “Self-association of β-amyloid peptide (1–40) in solution and binding to lipid membranes,” 
*Journal of Molecular Biology*, vol. 252, no. 5, pp. 633–642, 1995.

[28] L. P. Choo-Smith, W. Garzon-Rodriguez, C. G. Glabe, and W. K. Surewicz, “Acceleration of amyloid fibril formation by specific binding of Aβ-(1–40) peptide to ganglioside-containing membrane vesicles,” 
*Journal of Biological Chemistry*, vol. 272, no. 37, pp. 22987–22990, 1997.

[29] K. Matsuoka and C. Horikiri, “Interactions of amyloid β-peptide (1–40) with ganglioside-containing membranes,” 
*Biochemistry*, vol. 38, no. 13, pp. 4137–4142, 1999.

[30] J. McLaurin and A. Chakrabarty, “Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity,” 
*Journal of Biological Chemistry*, vol. 271, no. 43, pp. 26482–26489, 1996.

[31] J. McLaurin, T. Franklin, P. E. Fraser, and A. Chakrabarty, “Structural transitions associated with the interaction of Alzheimer β-amyloid peptides with gangliosides,” 
*Journal of Biological Chemistry*, vol. 273, no. 8, pp. 4506–4515, 1998.

[32] L. P. Choo-Smith and W. K. Surewicz, “The interaction between Alzheimer amyloid β(1–40) peptide and ganglioside G(M1)-containing membranes,” 
*FEBS Letters*, vol. 402, no. 2, pp. 95–98, 1997.

[33] T. Ariga, K. Kobayashi, A. Hasegawa, M. Kiso, H. Ishida, and T. Miyatake, “Characterization of high-affinity binding between gangliosides and amyloid β-protein,” 
*Archives of Biochemistry and Biophysics*, vol. 388, no. 2, pp. 225–230, 2001.

[34] P. K. Mandal and J. W. Pettigrew, “Alzheimer’s disease: NMR studies of asialo (GM1) and Trisialo (GT1b) ganglioside interactions with Aβ(1–40) peptide in a membrane mimic environment,” 
*Neurochemical Research*, vol. 29, no. 2, pp. 447–453, 2004.

[35] Y. Nakazawa, Y. Suzuki, M. P. Williamson, H. Saiťo, and T. Asakura, “The interaction of amyloid Aβ-(1–40) with lipid bilayers and ganglioside as studied by P solid-state NMR,” 
*Chemistry and Physics of Lipids*, vol. 158, no. 1, pp. 54–60, 2009.

[36] C. S. Atwood, R. D. Moir, X. Huang et al., “Dramatic aggregation of alzheimer by Cu(II) is induced by conditions representing physiological acidosis,” 
*Journal of Biological Chemistry*, vol. 273, no. 21, pp. 12817–12826, 1998.

[37] Y. R. Chen, H. B. Huang, C. L. Chyan, M. S. Shiao, T. H. Lin, and Y. C. Chen, “The effect of Aβ conformation on the metal affinity and aggregation mechanism studied by circular dichroism spectroscopy,” 
*Journal of Biochemistry*, vol. 139, no. 4, pp. 733–740, 2006.

[38] M. P. Williamson, Y. Suzuki, N. T. Bourne, and T. Asakura, “Binding of amyloid β-peptide to ganglioside micelles is dependent on histidine-13,” 
*Biochemical Journal*, vol. 397, no. 3, pp. 483–490, 2006.

[39] H. Zhang, J. Ding, W. Tian et al., “Ganglioside GM1 binding the N-terminus of amyloid precursor protein,” 
*Neurobiology of Aging*, vol. 30, no. 8, pp. 1245–1253, 2009.

[40] M. Usumi, Y. Yamaguchi, H. Sasakiwa, N. Yamamoto, K. Yanagisawa, and K. Kato, “Up-and-down topological mode
of amyloid $\beta$-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters,” *Glycoconjugate Journal*, vol. 26, no. 8, pp. 999–1006, 2009.

[41] M. Yagi-Utsumi, T. Kameda, Y. Yamaguchi, and K. Kato, “NMR characterization of the interactions between lyso-GM1 aqueous micelles and amyloid $\beta$,” *FEBS Letters*, vol. 584, no. 4, pp. 831–836, 2010.

[42] K. Yanagisawa, A. Odaka, N. Suzuki, and Y. Ihara, “GM1 ganglioside-bound amyloid $\beta$-protein (AB): a possible form of preamyloid in Alzheimer’s disease,” *Nature Medicine*, vol. 1, no. 10, pp. 1062–1066, 1995.

[43] K. Yanagisawa, “Role of gangliosides in Alzheimer’s disease,” *Biochimica et Biophysica Acta*, vol. 1768, no. 8, pp. 1943–1951, 2007.

[44] K. Yanagisawa and Y. Ihara, “GM1 ganglioside-bound amyloid $\beta$-protein in Alzheimer’s disease brain,” *Neurobiology of Aging*, vol. 19, no. 1, pp. S65–S67, 1998.

[45] N. Kimura and K. Yanagisawa, “Endosomal accumulation of GM1 ganglioside-bound amyloid $\beta$-protein in neurons of aged monkey brains,” *NeuroReport*, vol. 18, no. 16, pp. 1669–1673, 2007.

[46] B. Kurganov, M. Doh, and N. Arispe, “Aggregation of liposomes induced by the toxic peptides Alzheimer’s AFs, human amylin and prion (106–126): facilitation by membrane-bound GM1 ganglioside,” *Peptides*, vol. 25, no. 2, pp. 217–232, 2004.

[47] N. Yamamoto, Y. Hirabayashi, M. Amari et al., “Assembly of hereditary amyloid $\beta$-protein variants in the presence of favorable gangliosides,” *FEBS Letters*, vol. 579, no. 10, pp. 2185–2190, 2005.

[48] T. Okada, K. Ikeda, M. Wakabayashi, M. Ogawa, and K. Matsuzaki, “Formation of toxic A$\beta$(1–40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in A$\beta$(1–40) fibrils,” *Journal of Molecular Biology*, vol. 382, no. 4, pp. 1066–1074, 2008.

[49] K. Yanagisawa, “Cholesterol and A$\beta$ aggregation,” *Pharmacopsychiatry*, vol. 36, no. 2, pp. S127–S129, 2003.

[50] K. Yanagisawa and K. Matsuzaki, “Cholesterol-dependent aggregation of amyloid $\beta$-protein,” *Annals of the New York Academy of Sciences*, vol. 977, pp. 384–386, 2002.

[51] M. Wakabayashi and K. Matsuzaki, “Formation of amyloids by A$\beta$-(1–42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol,” *Journal of Molecular Biology*, vol. 371, no. 4, pp. 924–933, 2007.

[52] S. S. S. Wang, D. L. Rymer, and T. A. Good, “Reduction in cholesterol and sialic acid content protects cells from the toxic effects of $\beta$-amyloid peptides,” *Journal of Biological Chemistry*, vol. 276, no. 45, pp. 42027–42034, 2001.

[53] M. S. Lin, L. Y. Chen, S. S. Wang, Y. Chang, and W. Y. Chen, “Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide,” *Colloids and Surfaces B*, vol. 65, no. 2, pp. 172–177, 2008.

[54] Q. Zha, Y. Ruan, T. Hartmann, K. Beyreuther, and D. Zhang, “GM1 ganglioside regulates the proteolysis of amyloid precursor protein,” *Molecular Psychiatry*, vol. 9, no. 10, pp. 946–952, 2004.

[55] H. Hayashi, N. Kimura, H. Yamaguchi et al., “A seed for Alzheimer amyloid in the brain,” *Journal of Neuroscience*, vol. 24, no. 20, pp. 4894–4902, 2004.

[56] K. Yuyama and K. Yanagisawa, “Late endocytic dysfunction as a putative cause of amyloid fibril formation in Alzheimer’s disease,” *Journal of Neurochemistry*, vol. 109, no. 5, pp. 1250–1260, 2009.

[57] N. Yamamoto, T. Matsubara, T. Sato, and K. Yanagisawa, “Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid $\beta$-protein fibrillogenesis,” *Biochimica et Biophysica Acta*, vol. 1778, no. 12, pp. 2717–2726, 2008.
[72] M. Yanagisawa, T. Ariga, and R. K. Yu, “Fucosyl-GM1 expression and amyloid-β protein accumulation in PC12 cells,” *Journal of Neuroscience Research*, vol. 84, no. 6, pp. 1343–1349, 2006.

[73] T. Ariga, K. Kobayashi, Y. Kuroda et al., “Characterization of tumor-associated fucogangliosides from PC 12 pheochromocytes cells,” *Journal of Biological Chemistry*, vol. 262, no. 29, pp. 14146–14153, 1987.

[74] Y. Yamazaki, Y. Horibata, Y. Magatsu, Y. Hirabayashi, and T. Hashikawa, “Fucoganglioside α-fucosyl-(α-galactosyl)-GM1: a novel member of lipid membrane microdomain components involved in PC12 cell neuritogenesis,” *Biochemical Journal*, vol. 407, no. 1, pp. 31–40, 2007.

[75] T. Ariga, L. J. Macala, M. Saito et al., “Lipid composition of PC12 pheochromocytoma cells: characterization of globo-side as a major neutral glycolipid,” *Biochemistry*, vol. 27, no. 1, pp. 52–58, 1988.

[76] M. Molander-Melin, K. Blennow, N. Bogdanovic, B. Dellheiden, J. E. Månsson, and P. Fredman, “Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains,” *Journal of Neurochemistry*, vol. 92, no. 1, pp. 171–182, 2005.

[77] G. P. Eckert, W. G. Wood, and W. E. Müller, “Lipid membranes and β-amyloid: a harmful connection,” *Current Protein and Peptide Science*, vol. 11, no. 5, pp. 319–325, 2010.

[78] S. Kalanj, I. Kracun, H. Rosner, and C. Cosovíc, “Regional distribution of brain gangliosides in Alzheimer’s disease,” *Neurologia Croatica*, vol. 40, no. 4, pp. 269–281, 1991.

[79] S. Kalanj-Bognar, “Ganglioside catabolism is altered in fibroblasts and leukocytes from Alzheimer’s disease patients,” *Neurobiology of Aging*, vol. 27, no. 9, pp. 1354–1356, 2006.

[80] L. Svennerholm and C. G. Gottfries, “Membrane lipids, components involved in PC12 cell neuritogenesis,” *Biochemical Journal*, vol. 27, no. 1, pp. 123–130, 1988.

[81] T. Ariga, Y. Tanaka, S. Kobayashi et al., “Synaptic function of cholinergic-specific ganglioside in bovine brain,” *Journal of Biological Chemistry*, vol. 267, no. 18, pp. 12973–12978, 1992.

[82] E. A. Derrington and E. Borroni, “The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat,” *Developmental Brain Research*, vol. 52, no. 1-2, pp. 131–140, 1990.

[83] S. Ando, Y. Tanaka, S. Kobayashi et al., “Synaptic function of cholinergic-specific Chol-1α ganglioside,” *Neurochemical Research*, vol. 29, no. 4, pp. 857–867, 2004.

[84] S. Ando, Y. Tanaka, H. Waki, K. Kon, M. Iwamoto, and F. Fukui, “Gangliosides and sialylcholesterol as modulators of synaptic functions,” *Annals of the New York Academy of Sciences*, vol. 845, pp. 232–239, 1998.

[85] N. S. Hong, D. H. Kwon, and G. S. Dawe, “Effect of voluntary running on adult hippocampal neurogenesis in cholinergic lesioned mice,” *BMC Neuroscience*, vol. 10, article 57, 2009.

[86] D. A. Greenberg and K. Jin, “Neurodegeneration and neurogenesis: focus on Alzheimer’s disease,” *Current Alzheimer Research*, vol. 3, no. 1, pp. 25–28, 2006.

[87] K. Jin, V. Galvan, L. Xie et al., “Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APP ) mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 36, pp. 13363–13367, 2004.

[88] M. A. Lopez-Toledano, M. A. Faghhi, N. S. Patel, and C. Walestedt, “Adult neurogenesis: a potential tool for early diagnosis in alzheimer’s disease?” *Journal of Alzheimer’s Disease*, vol. 20, no. 2, pp. 395–408, 2010.

[89] M. A. Lopez-Toledano and M. L. Shelanski, “Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind),” *Journal of Alzheimer’s Disease*, vol. 12, no. 3, pp. 229–240, 2007.

[90] N. Oikawa, H. Yamaguchi, K. Ojiro et al., “Gangliosides determine the amyloid pathology of Alzheimer’s disease,” *NeuroReport*, vol. 20, no. 12, pp. 1043–1046, 2009.

[91] M. Okada, M.-I. Itoh, M. Haraguchi et al., “β-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve,” *Journal of Biological Chemistry*, vol. 277, no. 3, pp. 1633–1636, 2002.

[92] G. C. Gregory, V. Macdonald, P. R. Schofield, J. J. Kril, and G. M. Halliday, “Differences in regional brain atrophy in genetic forms of Alzheimer’s disease,” *Neurobiology of Aging*, vol. 27, no. 3, pp. 387–393, 2006.
[134] S. Tsuji, T. Yamashita, and Y. Nagai, “A novel, carbohydrate signal-mediated cell surface protein phosphorylation: ganglioside GQ1b stimulates ecto-protein kinase activity on the cell surface of a human neuroblastoma cell line, GOTO,” *Journal of Biochemistry*, vol. 104, no. 4, pp. 498–503, 1988.

[135] J. L. Jankowsky, H. H. Slunt, T. Ratovitski, N. A. Jenkins, N. G. Copeland, and D. R. Borchelt, “Co-expression of multiple transgenes in mouse CNS: a comparison of strategies,” *Biomolecular Engineering*, vol. 17, no. 6, pp. 157–165, 2001.

[136] L. Wu, A. A. Sluiter, H. F. Guo et al., “Neural stem cells improve neuronal survival in cultured postmortem brain tissue from aged and Alzheimer patients,” *Journal of Cellular and Molecular Medicine*, vol. 12, no. 5A, pp. 1611–1621, 2008.

[137] K. Matsuzaki, T. Noguch, M. Wakabayashi et al., “Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes,” *Biochimica et Biophysica Acta*, vol. 1768, no. 1, pp. 122–130, 2007.

[138] L. Svennerholm, “The gangliosides,” *Journal of Lipid Research*, vol. 5, no. 4, pp. 145–126, 1964.